|
Full-length sucrose-formulated recombinant factor VIII for
treatment of previously untreated or minimally treated young
children with severe haemophilia A
Results of an international clinical investigation
Wolfhart Kreuz, Joan C. Gill1, Chantal Rothschild2, Marilyn J. Manco-Johnson3, Jeanne M. Lusher4, Elke Kellermann5,
Eduard Gorina6, Peter J. Larson6 and the International Kogenate-FS Study Group
The Center of Pediatrics III, Department of Hematology, Oncology and Hemostaseology, Johann Wolfgang Goethe-University Hospital,
Frankfurt am Main, Germany
1Blood Center of Southeastern Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
2Hôpital Necker, Centre de l'Hemophilie F. Josso, Paris, France
3Department of Pediatrics, University of Colorado Health Sciences Center, Denver, Colorado, USA
4Children's Hospital of Michigan, Detroit, Michigan, USA
5Bayer Vital GmbH Biological Products, Leverkusen, Germany
6Bayer HealthCare, Biological Products Division, Research Triangle Park, North Carolina, USA
原文下载：Kogenate FS对既往未接受治疗的重型血友病A患儿安全有效
|
